BCL2 and diffuse large B-cell lymphoma: Importantly, our results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of immunohistochemical subgroups (GCB and non-GCB), IPI, BCL2 protein, and BCL2/BCL6 DHS, but enhances the prognostic value of Ki67 in DLBCL.